COST-EFFECTIVENESS OF FINGOLIMOD, TERIFLUNOMIDE, DIMETHYL FUMARATE AND INTRAMUSCULAR INTERFERON BETA-1A IN RELAPSING-REMITTING MULTIPLE SCLEROSIS

被引：3
|
作者：
Zhang, X. [1 ]
Hay, J. W. [1 ]
机构：
[1] Univ So Calif, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.351
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND20
引用
收藏
页码：A59 / A60
页数：2
相关论文
共 50 条
  • [31] Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study
    Khatri, Bhupendra
    Barkhof, Frederik
    Comi, Giancarlo
    Hartung, Hans-Peter
    Kappos, Ludwig
    Montalban, Xavier
    Pelletier, Jean
    Stites, Tracy
    Wu, Stacy
    Holdbrook, Fred
    Zhang-Auberson, Lixin
    Francis, Gordon
    Cohen, Jeffrey A.
    Cohen, J.
    Barkhof, F.
    Comi, G.
    Hartung, H.P.
    Khatri, B.
    Montalban, X.
    Pelletier, J.
    Easton, D.
    Calandra, T.
    DiMarco, J.
    Hudson, L.
    Kesselring, J.
    Laupacis, A.
    Temkin, N.
    Weinshenker, B.
    Zarbin, M.
    Barkhof, F.
    Poppe, P.
    Luetic, G.
    Cristiano, E.
    Caceres, F.
    Garcea, O.
    Correale, J.
    Ballario, C.
    Piedrabuena, R.
    Pollard, J.
    Beran, R.
    Hodgkinson, S.
    Schwartz, R.
    Heard, R.
    King, J.
    Butzkueven, H.
    Maida, E.M.
    Vass, K.
    Franta-Elmer, C.
    Berger, T.
    Aichner, F.
    LANCET NEUROLOGY, 2011, 10 (06): : 520 - 529
  • [32] Cost-effectiveness of alemtuzumab vs subcutaneous interferon beta-1a for treatment of active relapsing-remitting multiple sclerosis: payer perspective
    Celestin, C.
    Cutter, G. R.
    Coles, A. J.
    Reimers, A.
    Margolin, D. H.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 72 - 72
  • [33] The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada
    Su, Wenqing
    Kansal, Anuraag
    Vicente, Colin
    Deniz, Baris
    Sarda, Sujata
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (07) : 718 - 727
  • [34] Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients
    Rudick, R. A.
    Kappos, L.
    Kinkel, R.
    Clanet, M.
    Phillips, J. T.
    Herndon, R. M.
    Sandrock, A. W.
    Munschauer, F. E., III
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (03) : 353 - 360
  • [35] Dimethyl fumarate versus interferon for treatment of relapsing-remitting multiple Sclerosis
    Sattarnezhad, Neda
    Healy, Brian C.
    Baharnoori, Moogeh
    Diaz-Cruz, Camilo
    Stankiewicz, James
    Weiner, Howard L.
    Chitnis, Tanuja
    NEUROLOGY, 2017, 88
  • [36] Interferon beta-1a in relapsing-remitting multiple sclerosis: A meta-analysis
    Blumhardt, LD
    NEUROLOGY, 1999, 52 (06) : A498 - A498
  • [37] Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
    Vazquez Gomez, Lazaro Aurelio
    Hidalgo Mesa, Carlos
    Broche Perez, Yunier
    Valdes Morales, Yanet
    MEDISUR-REVISTA DE CIENCIAS MEDICAS DE CIENFUEGOS, 2022, 20 (05): : 825 - 833
  • [38] Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis
    Munschauer, FE
    Stuart, WH
    CLINICAL THERAPEUTICS, 1997, 19 (05) : 868 - 882
  • [39] Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia
    Lasalvia, Pieralessandro
    Hernandez, Fabian
    Castaneda-Cardona, Camilo
    Andres Cuestas, J.
    Rosselli, Diego
    VALUE IN HEALTH REGIONAL ISSUES, 2020, 23 : 13 - 18
  • [40] COST-EFFECTIVENESS OF ALEMTUZUMAB FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Kohn, Christine G.
    Costales, Victoria
    Coleman, Craig I.
    Young, Dan
    Limone, Brendan L.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (10) : 1413 - 1414
12345